anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Part 1 was a dose escalation study in subjects with any BRAF V600 mutation-positive solid tumor, designed to optimize efficiency of enrollment, minimize the number of subjects being treated at potentially sub-efficacious dose levels, and incorporating the evolving pharmacokinetic, safety and efficacy data from the adult development program. Dose escalation part of the study was to determine the maximum tolerated dose (MTD) and recommend the dose for phase 2 studies (RP2D). An MTD has not been identified for dabrafenib in the adult population. This does not preclude the identification of an MTD in the pediatric population. Modified RSD was employed to determine the MTD. Part 1 used dual criteria of dose limiting toxicity (DLT) and observed dabrafenib exposures to make decisions to advance to the next dose level. Target exposure criteria based on adults treated at the approved adult dose of 300 mg (150 mg given BID) were observed in this study before meeting criteria for stopping dose escalation due to observations of DLTs, and served as the criteria for determining the RP2D for dabrafenib in pediatric subjects. Thus, MTD has not been established in pediatric population, similar to the previous dose finding efforts in adult subjects.

Part 2 was a tumor specific expansion study to further evaluate the safety/tolerability profile and to discover possible clinical efficacy of dabrafenib in 4 tumor-specific pediatric populations known to have BRAFV600 activation: high grade glioma (HGG), low grade glioma (LGG), Langerhans cell histiocytosis (LCH), miscellaneous tumors including melanoma and papillary thyroid carcinoma (Other). The exposures for subjects dosed on the basis of weight were also evaluated by age categories.
Epilepsy is a disorder of the brain characterized by an enduring predisposition to generate seizures and by the neurobiologic, cognitive, psychological and social consequences of this condition. Epilepsy is a disabling and common neurological condition which rank 4th in the world's neurological disorder burden, which can be controlled successfully in most of the patients with one or more antiepileptic drugs. But approximately 30% of patients with epilepsy have refractory epilepsy, which is, a failure to respond to adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules to achieve sustained relief of seizures.Many severe and catastrophic epilepsies present in children such as West syndrome, Lennox Gastaut syndrome, Dravet syndrome. Uncontrolled epilepsy carries significant risks for the affected child, such as injuries, cognitive and behavioural problems. Epilepsy surgery is a good option but it is expensive and not easily available. Also, many children with refractory epilepsy are not good surgical candidates. Hence there is a need to consider alternative treatments in these children.

The ketogenic diet is an individually calculated and rigidly controlled high-fat, low carbohydrate diet used for the treatment of difficult to control seizures. The ketogenic diet is an effective treatment option for refractory childhood epilepsy however it is very restrictive and difficult to implement in low resource settings. The modified Atkins diet is a less restrictive alternative to the traditional ketogenic diet. This diet is started on an outpatient basis without a fast, and allows unlimited protein and fat. This diet has been shown to be equally effective as the ketogenic diet and a useful option in resource-constraint settings. The modified Atkins diet has been demonstrated to be effective in refractory childhood epilepsy in two randomized controlled trials from India. However, in both these trials the control groups continued their ongoing antiepileptic medication without any new treatment.

Levetiracetam is one of the newer antiepileptic drugs available for treating drug resistant epilepsy. It is a broad-spectrum antiepileptic drug effective in most seizure types. It also has an excellent pharmacokinetics and tolerability profile with no known pharmacokinetic interactions. Use of levetiracetam as an add on drug in refractory childhood epilepsy recently in some published studies has shown good efficacy.

In this study, the efficacy of add-on modified Atkins diet will be compared with add-on Levetiracetam in children with refractory epilepsy in a randomized open label trial. The results will aid clinicians in deciding the treatment options when a child has been diagnosed to have refractory epilepsy.
PURPOSE: To obtain a cosmetic and pharmaceutical composition comprising a liposome containing an active compound. CONSTITUTION: This cosmetic and pharmaceutical composition contains a liposome containing at least one kind of a compound of formula I [R1 is cyano, nitro or a halogen; R2 is trifluoromethyl or a halogen; the group A-B is formulas II or III (X is O or S; R3 is H, an alkyl, an aryl, etc.); Y is O, S or =NH]. The liposome is prepared by formulating 0.001-20 wt.% of the active compound of formula I based on the total of the composition, and further one or more kinds of lipid compounds (e.g. phospholipid E100. 35), a pH buffer, an antioxidant, a preservative, etc., to form an aqueous emulsion or suspension, stirring the, obtained emulsion or suspension at 40-80 deg.C, subjecting the stirred emulsion or suspension to a finely fluidizing apparatus to reduce the largeness of the liposome.  The composition is used for treatment of adenoma of prostate gland and neoplasia, treatment of prostatomegaly, and treatment of cancer of the breast, the skin, the ovajy, the bladder, etc., acne, seborrhoica, androgen alopecia, etc., and further used in cosmetics and cosmetology.
BACKGROUND: Limited evidence exists on the role of depression in the risk of developing stroke and other cardiovascular outcomes in patients who have undergone percutaneous coronary interventions (PCI). We investigated this relationship with data from the Korean National Health Insurance Service database.
METHODS: Our nationwide retrospective cohort study included 164,198 patients who had undergone PCI between 2010 and 2017. Depression was defined with the ICD-10 codes recorded prior to the PCI. The primary outcome was a new-onset stroke following the PCI. Secondary outcomes included PCI with myocardial infarction (MI), revascularization (PCI or coronary artery bypass grafting), and all-cause mortality. A multivariable Cox proportional hazards regression analysis was used to calculate adjusted hazard ratios (aHR) and 95% confidence intervals (CI), adjusting for potential confounders, including sociodemographic and lifestyle factors, comorbidities, and MI at the index PCI.
RESULTS: Over a median follow-up of 5.0 years, acute stroke occurred in 5.7% of patients with pre-existing depression (17.4% of the study population), compared to 3.5% of those without depression. Depression was associated with a 27% increased risk of acute stroke (aHR 1.27, 95% CI 1.20-1.35). Additionally, depression was linked with a 25% elevated risk of all-cause death (aHR 1.25, 95% CI, 1.21-1.29) and an 8% increased risk of revascularization (aHR 1.08, 95% CI 1.04-1.11). The associations with the risk of stroke and all-cause mortality were stronger in patients under 65 years.
CONCLUSIONS: Our findings suggest that pre-existing depression may increase the risk of stroke and all-cause mortality following PCI, particularly in patients under 65 years. Additionally, depression was significantly associated with an increased need for revascularization. This underscores the potential benefits of managing depression to reduce stroke risk and overall cardiovascular outcomes following PCI.
The invention relates to a Smilax scobinicaulis C.H. Wright oral liquid used for wind dispelling and dampness disinhibiting, and a production method thereof. The oral liquid is formed by Smilax scobinicaulis C.H. Wright, nutgall, Chinese holly leaf, Hedyotis diffusa, Radix Boehmeriae, lily, Glabrous Greenbrier Rhizome, hyacinth bean flower, lotus peduncle and Scutellaria lateriflora. The method mainly comprises the following steps: choosing materials, drying the chosen materials, crushing the dried materials, proportioning the crushed materials, boiling the obtained mixture, diluting the boiled mixture, seasoning the diluted mixture, and bottling the seasoned mixture to obtain the finished product. The oral liquid has the advantages of wind dispelling and dampness disinhibiting integration, pure naturalness, no toxic or side effects, high absorption rate, obvious nourishing effect, effective improvement of human body functions, and increase of the human body immunity.
In Period 1, participants will receive single oral dose of Cytochrome P450 (CYP) substrates on Day 1. In Period 2, three IV doses of risankizumab on Days 1, 29 and 57, followed by single oral dose of CYP substrates on Day 64 will be administered.
The invention relates in a first aspect to an azadibenzocyclooctyne derivative according to formula (I) or a salt thereof having specific substituents at the benzo rings of the DIBAC structure and having specific substituents connected to the nitrogen atom of the DIBAC structure. A second aspect of the invention is directed to a conjugate of formula (II), wherein a substituent R 6  is connected to the N atom of the 8 membered ring of the DIBAC structure via a linker structure –C(=O)-[L] n -Z-. A third aspect of the invention relates to a method for the modification of a target molecule, wherein a conjugate according to the second aspect is reacted with a target molecule comprising a 1,3-dipole group or a 1,3-(hetero)diene group. In a fourth aspect, the invention is directed to the use of the conjugate according to the second aspect for bioorthogonal labeling and/or modification of a target molecule. A fifth aspect of the invention relates to a modified target molecule comprising the reaction product of a conjugate according to the second aspect and a target molecule comprising a 1,3-dipole group or a 1,3-(hetero)diene group, obtained or obtainable from the method of the third aspect. In a sixth aspect, the invention is related to a kit comprising a modified target molecule according to the fifth aspect as detector reagent and a suitable capture reagent.
Ten patients undergo MR-HIFU ablation with the Sonalleve MR-HIFU Breast Tumor Therapy System (Profound Medical). According to a treat-and-resect protocol, these patients also undergo standard therapy consisting of breast cancer surgery 1 to 2 weeks after MR-HIFU treatment (+/- radiotherapy).
PURPOSE: People with multiple sclerosis (pwMS) experience autoimmunity-mediated inflammation and neurodegeneration throughout the central nervous system. There remains a need for clinically accessible, reliable functional markers of neurodegeneration in MS. Previous research has described changes to electroretinography (ERG)-derived measures of retinal bipolar cell function in pwMS early in the disease course. We, therefore, investigated ERG as a potential outcome measure in individuals with more advanced disease.
METHODS: This cross-sectional observational study included pwMS with Expanded Disability Status Scale (EDSS) scores of ≥3.0 and healthy control (HC) participants who underwent ERG, optical coherence tomography, high- and low-contrast visual acuity measurement, and an ophthalmological examination. ERG findings in MS eyes with and without previous optic neuritis (MS +ON; MS -ON) were compared with those in HC eyes. Effects of EDSS, disease duration, ON, and treatment status on selected ERG outcomes were measured. Additional exploratory analyses assessed potential influences of MS phenotype and disease status (clinically active, radiologically active, and disease progression).
RESULTS: Delays to two ERG peak times (dark-adapted 3.0 b-wave; light-adapted flicker) were recorded in MS +ON and MS -ON eyes. No influences of EDSS score, disease duration, previous ON, or treatment status were observed. Exploratory analyses were consistent with no effects of MS phenotype or disease status.
CONCLUSIONS: ERG findings are abnormal in individuals with moderate-severe disability caused by MS; however, these findings are not distinct from those observed earlier in the disease course. Although bipolar dysfunction appears to be common in pwMS throughout the disease course, ERG is likely not useful in monitoring or prognostication of MS.
Useful products are recovered from citrus peel waste by extraction with a non-aqs. water muscible solvent to leave a product high in cellulose and pectin. The extract is diluted with water to release the extracted essential oils which are then separated. The non-aqs. solvent is removed from the aq. layer to ppt. bioflavanoids and leave a sugar syrup. The citrus peel is coarsely ground, steamed to soften it and then may be extruded in a screw flusher to remove seeds, stems or leaves. The non-aqs. solvents include lower alkanols, lower ketones, and mono- or di-alkyl ethers of ethylene glycol and their esters and these recover essential oils (e.g. d-laminene) and oil soluble components such as carotene, chlorophyll and flavanonoids such as hesperidin. The residual pref. contg. cellulose and pectan is used as hypochlolesterolaemic agent, humectant for food, mold inhibitor and viscosity increases for drilling mud. The sugar syrup may be used as a natural sweetener for food. -
Subjects randomized to this group will receive access to WSM and group support and clinical expert support. They will attend 4 weekly support groups led by a peer non-expert facilitator and 4 weekly support groups led by a clinical psychologist.
FIELD: traumatology and crisis therapy. SUBSTANCE: patients undergo artificial pulmonary ventilation with change of on-back and on-belly positions at 12-h intervals. Sanative fibrobronchoscopy is performed every 6 h with on-back and on-belly positions. Endotracheal inhalation for broncholith patients is performed for 10 min at 3-h intervals. Treatment is administered regularly for 7 to 14 days to achieve cup-off of respiratory insufficiency and consciousness recovery. Such treatment results in improved drainage function of tracheobronchial tree. EFFECT: reduced treatment time.
PURPOSE:To obtain the titled regulator, containing a growth factor and a peptide corresponding to part of constituent ingredients thereof as an active ingredient and capable of enhancing the anticancer actin of a compound having the anticancer action and relieving side effects thereof. CONSTITUTION:An anticancer action regulator containing a growth factor such as epithelial cell growth factor group, e.g. human epithelial cell growth factor (hEGF), insulin group, blood platelet-derived growth factor group, e.g. fibroblastic growth factor, etc., and a peptide corresponding to part of constituent ingredients thereof, derivative or salt thereof as an active ingredient. A derivative in which methionine at the 21st residue from the N-terminal is converted into leucine in 53 amino acid residues constituting the hEGF, two of leucine and arginine deficient in the C-terminal, etc., are cited as the above- mentioned derivative. The dose of the above-mentioned regulator is preferably about 10ng-10mg expressed in terms of the growth factor, etc., a day for an adult and the regulator is also effectively used as a radiosensitizer in radiotherapy.
FIELD: medicine. SUBSTANCE: method involves administration of medicinal herb infusion at therapeutic doses taken at equal ratios by mass for 0.5-2 months in combination with enterosorbent. Herbal species has common immortelle flowers, marjoram herb, Jerusalem-sage herb, nettle herb, pot-marigold flowers, tormentil roots, peppermint leaves, wild carrot seeds, colt's foot herb, common wormwood herb, matricary flowers, milfoil herb, dill seeds, hop cones, sage leaves, trefoil leaves, erva woolly herb, rose fruits and coriander seeds. Method can involves additional bile duct clearing with the use of vegetable oil. Before oil administration patient takes enterosorbent and spasmolytic and after vegetable oil taking heat is applied on reflexogenic zones (start point of liver and gall bladder meridians, first and ring finger of foot). Maize oil is taken as vegetable oil. Method ensures to soft, grind and dissolve gallstones partially and remove their from organism being without surgery operation. EFFECT: enhanced effectiveness of method. 3 cl, 1 tbl
The invention develops a powder which is developed by taking dark plum (Prunus mume Sieb. Et Zucc) and bamboo leaves as raw materials, has thrombus-reducing activity and can be directly used in a proper dosage form. Taking dried folium Bambusae and mume fructus (core removed), pulverizing respectively, soaking in 80% edible alcohol with liquid-material ratio of 5-6, and heating and refluxing at 80 deg.C for 5 hr. Cooling the extractive solution to room temperature, filtering, and evaporating the solvent in a rotary evaporator (water bath temperature 50 deg.C, vacuum degree-0.1 MPa) to obtain extracts of herba Lophatheri and mume fructus. Mixing the extract of 2 parts of moso bamboo leaves and the extract of 1 part of dark plum in an optimal proportion for later use. Adding distilled water with the same weight into milk powder prepared from whole milk without any addition, and preparing into milk product containing 0.457 +/-0.002 kg of milk powder per kg for later use. Taking 5 parts of maltodextrin (DE20), 10 parts of extraction mixture and 5 parts of cane sugar by weight, adding 15 parts of prepared milk product, and uniformly stirring. Freeze-drying at-30 deg.C under 0.5mm Hg for 50 hr. Crushing, sieving, and bottling. The extracted mixture is proved to have remarkable pharmacological activity of inhibiting platelet aggregation through an artery-vein bypass thrombosis test.
PURPOSE OF REVIEW: To summarize and evaluate the literature on treatment approaches for oligometastatic and locally recurrent urothelial cancer.
RECENT FINDINGS: There is no clear definition for oligometastatic urothelial cancers due to limited data. Studies focusing on oligometastatic and locally recurrent urothelial cancer have been primarily retrospective. Treatment options include local therapy with surgery or radiation, and generalized systemic therapy such as chemotherapy or immunotherapy. Oligometastatic and locally recurrent urothelial cancers remain challenging to manage, and treatment requires an interdisciplinary approach. Systemic therapy is nearly always a component of current care in the form of chemotherapy, but the role of immunotherapy has not been explored. Consideration of surgical and radiation options may improve outcomes, and no studies have compared directly between the two localized treatment options. The development of new prognostic and predictive biomarkers may also enhance the treatment landscape in the future.
A wound debridement system includes a wound dressing having an active layer and a wound interface layer. The active layer is formed from one or more transmission layers that are arranged about a central post. Activation of the transmission layers is configured to cause the movement of the wound interface layer relative to a tissue site to which the wound dressing is applied. A drive unit is operably attached to the central post. The drive unit is configured to generate and transfer a vibrational energy and/or a rotational movement to the transmission layer(s) via the central post. The resultant vibration and/or rotation of the transmission layer(s) is imparted onto the wound interface layer, thereby effectuating the desired movement of the wound interface layer relative to the tissue site, which allows for the debridement of debris that may be located at the tissue site.
The patients will be divided into three research arms. Patients will be randomly selected for one of the groups using a random number generator between 1 and 3. There will be a "Control Group" which will receive a rectal exam while still in the operating room in the lithotomy position after the procedure. There will be a "Postoperative OR" group which will receive a B and O suppository while still in the operating room in the lithotomy position after the procedure. Finally, there will be a "Preoperative OR" group which will receive a B and O suppository after the induction of anesthesia prior to beginning the urologic procedure in the lithotomy position. The "Control Group" will receive a rectal exam in the operating room after the procedure but before extubation to simulate the effects of suppository administration so that the investigators know that any effects are due to the medication and not to the placement of the suppository itself. Those patients in the "control group" may receive a B and O suppository as part of standard procedure in the post-operative period if these individuals experience any bladder spasms and wish to have this as a treatment. This administration will be at the discretion of the operating surgeon as it is in standard cases. Patients may also receive Ditropan in the post-operative setting, which is part of the standard procedure for treating bladder spasms following urologic procedures. Patients in the postoperative and preoperative OR groups will be offered Ditropan for any bladder spasms in the post-operative setting to control symptoms, which is part of the normal standard of care for anyone who has already received a B and O suppository with inadequate control of symptoms. All patients will be treated with a normal post-operative pain regimen which may include narcotics. This will be at the discretion of the treating physician.
INTRODUCTION: Obesity and ADHD have become increasingly common diagnoses. In the last decade, research has found that there is a high prevalence of obesity in patients with ADHD. The mainstays of management in the general population include lifestyle modifications, pharmacotherapies, and/or bariatric surgery. However, there is a lack of understanding of appropriate management of patients with both ADHD and obesity.
METHODS: We identified those with obesity for at least five consecutive years (BMI > 30) in the TriNetX database before separating into two groups based on the presence or absence of ADHD. We assessed both the distribution of treatment modalities and the change in average BMI over time in each of our four groups across 5 years.
RESULTS: Average BMI decreased over time in all groups, with the smallest change seen in the ADHD Pharmacology cohort (- 0.366 kg/m2) and the largest in the ADHD Surgery group (- 8.532 kg/m2). Average BMIs at the 5-year mark were significantly different.
CONCLUSION: Our research found that pharmacological management of individuals with ADHD was only half as effective for individuals with ADHD than our control. Though surgical management of patients with ADHD is roughly 20 times more effective in managing obesity, it was not used as frequently in comparison to medication for management of weight.
Living donation (LD) transplantation is the preferred treatment for kidney failure as compared to donation after brain death (DBD), but age may play a role. We compared the 1-year estimated glomerular filtration rate (eGFR) after kidney transplantation for recipients of LD and DBD stratified by recipient and donor age between 2015 and 2018 in a matched cohort. The strength of the association between donation type and 1-year eGFR differed by recipient age (P interaction < 0.0001). For LD recipients aged 40-54 years versus same-aged DBD recipients, the adjusted odds ratio (aOR) for eGFR ≥60 mL/min/1.73 m2 was 1.48 (95% CI: 1.16-1.90). For DBD recipients aged ≥ 60 years, the aOR was 0.18 (95% CI: 0.12-0.29) versus DBD recipients aged 40-54 years but was 0.91 (95% CI: 0.67-1.24) versus LD recipients aged ≥60 years. In the matched cohort, 4-year graft and patient survival differed by donor age and type. As compared with DBD grafts, LD grafts increased the proportion of recipients with 1-year eGFR ≥60 mL/min/1.73 m2. Recipients aged ≥60 years benefited most from LD transplantation, even if the donor was aged ≥60 years. For younger recipients, large age differences between donor and recipient could also be addressed with a paired exchange program.